Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8258817 | 1.00 | ITGB1 (0.52) | ITGB1ITGA4 | |
| SCHEMBL8293264 | 0.83 | MDM4 (0.49) | ITGB1ITGA4 | |
| SCHEMBL8259404 | 0.83 | CYP3A4 (0.44) | ITGB1ITGA4 | |
| SCHEMBL8254376 | 0.82 | CYP3A4 (0.47) | ITGB1ITGA4 | |
| SCHEMBL5805018 | 0.82 | CYP3A4 (0.47) | ITGB1ITGA4 | |
| SCHEMBL6513562 | 0.81 | ITGB1 (0.61) | ITGB1ITGA4 | |
| SCHEMBL5804893 | 0.79 | ITGA4 (0.64) | ITGB1ITGA4 | |
| SCHEMBL8259306 | 0.79 | CYP3A4 (0.44) | ITGB1ITGA4 | |
| SCHEMBL5910985 | 0.79 | CYP3A4 (0.44) | ITGB1ITGA4 | |
| SCHEMBL8258982 | 0.78 | ITGA4 (0.53) | ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060223846-A1 | Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2006-10-05 | — | — | US | disclosed |
| WO-2006096807-A1 | AZA-BRIDGED-BICYCLIC AMINO ACID DERIVATIVES AS ALPHA 4 INTEGRIN ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223846-A1 | Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists | ITGA4, ITGB4, ITGB7 | ITGB1 7/4885ITGA4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.